{"product_id":"sarepta-bcg-matrix","title":"Sarepta Therapeutics Boston Consulting Group Matrix","description":"\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eSarepta's BCG matrix shows investment prioritization, analyzing its products' market growth and share positions. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eSarepta's BCG Matrix streamlines complex data with a clear quadrant view, delivering a concise strategic overview. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eDelivered as Shown\u003c\/span\u003e\u003cbr\u003eSarepta Therapeutics BCG Matrix\u003c\/h2\u003e\n\u003cp\u003eThe Sarepta Therapeutics BCG Matrix preview displays the complete document you'll receive after purchase. This is the final, fully editable version—ready for immediate strategic application. No hidden content or watermarks; just the finished report. Download and immediately integrate it into your business analysis.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003ch2\u003eBCG Matrix Template\u003c\/h2\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDownload Your Competitive Advantage\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eSarepta Therapeutics' diverse portfolio includes groundbreaking gene therapies, each at a different stage of market presence. Their Exondys 51 represents a mature product, while other treatments are still emerging. This BCG Matrix preview gives a glimpse into where each product sits—Stars, Cash Cows, or Question Marks. Discover the strategic implications of their product mix.\u003c\/p\u003e\n\u003cp\u003eGet the full BCG Matrix report to uncover detailed quadrant placements, data-backed recommendations, and a roadmap to smart investment and product decisions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etars\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eELEVIDYS (delandistrogene moxeparvovec-rokl)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eELEVIDYS, Sarepta's gene therapy for Duchenne muscular dystrophy (DMD), is a \"star.\" The therapy brought in $384.2 million in net product revenue in Q4 2024. Its broad label covers most Duchenne patients, fueling high demand. ELEVIDYS is set to boost Sarepta's 2025 revenue significantly.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRNA-based PMOs (EXONDYS 51, VYONDYS 53, AMONDYS 45)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSarepta's RNA-based PMOs (EXONDYS 51, VYONDYS 53, AMONDYS 45) remain a star. These therapies generated $254.0 million in Q4 2024 revenue and $967.2 million for the full year. They continue to serve specific DMD patient populations. Their market presence remains strong alongside ELEVIDYS.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eLimb-girdle Muscular Dystrophy (LGMD) Pipeline\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSarepta's LGMD pipeline is poised to be a Star, with significant growth potential. The company is advancing gene therapy programs for various LGMD subtypes. SRP-9003, targeting LGMD 2B\/R2, is on track for a BLA submission to the FDA in the second half of 2025. This highlights Sarepta's commitment to addressing unmet medical needs.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003esiRNA Programs (Arrowhead Collaboration)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSarepta's partnership with Arrowhead Pharmaceuticals for siRNA programs is a smart move into a promising field. This collaboration gives Sarepta a wider range of clinical and preclinical programs. These siRNA programs could become major successes, with possible blockbuster potential in the late 2020s. The market for RNA-based therapeutics is expected to reach $44.1 billion by 2028, showing significant growth potential.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eStrategic Expansion:\u003c\/strong\u003e Sarepta diversifies its pipeline with siRNA programs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eMarket Opportunity:\u003c\/strong\u003e RNA therapeutics market is set to grow significantly by 2028.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCollaboration Benefits:\u003c\/strong\u003e Access to multiple clinical and preclinical programs.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFuture Potential:\u003c\/strong\u003e Anticipated blockbuster opportunities in 2028 and 2029.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eFinancial Performance \u0026amp; Growth\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSarepta Therapeutics shines as a Star due to its robust financial performance. The company's net product revenues surged by 75% in Q4 2024, reaching $638.2 million. This strong growth, combined with GAAP net income of $159.0 million and non-GAAP net income of $206.0 million, showcases its potential.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eQ4 2024 Net Product Revenues: $638.2 million\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eQ4 2024 GAAP Net Income: $159.0 million\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eQ4 2024 Non-GAAP Net Income: $206.0 million\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Stars-Star-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSarepta's Revenue Soars: ELEVIDYS and PMOs Lead the Way!\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSarepta's ELEVIDYS and RNA-based PMOs are key Stars. ELEVIDYS had $384.2M in Q4 2024 revenue, with the PMOs at $254.0M. LGMD pipeline also shows Star potential with SRP-9003 BLA submission in 2025. Sarepta's net product revenues rose to $638.2M in Q4 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eTherapy\u003c\/th\u003e\n\u003cth\u003eQ4 2024 Revenue\u003c\/th\u003e\n\u003cth\u003eNotes\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eELEVIDYS\u003c\/td\u003e\n\u003ctd\u003e$384.2M\u003c\/td\u003e\n\u003ctd\u003eGene therapy for DMD.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePMOs\u003c\/td\u003e\n\u003ctd\u003e$254.0M\u003c\/td\u003e\n\u003ctd\u003eRNA-based therapies.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLGMD Pipeline\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003eBLA submission planned.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eC\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eash Cows\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEXONDYS 51\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eEXONDYS 51, an established DMD therapy, is a cash cow for Sarepta. It uses exon-skipping tech and PMO chemistry, ensuring steady sales. Despite competition, it generates stable revenue. In Q3 2024, EXONDYS 51 sales were $89.4 million. This solidifies its cash cow status.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eVYONDYS 53\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eVYONDYS 53, a PMO-based therapy from Sarepta, targets a specific exon mutation in DMD patients, bolstering cash flow. Its established market position and dedicated patient base, like EXONDYS 51, ensure revenue. In 2024, VYONDYS 53 generated approximately $400 million in sales. While growth is moderate, it's a dependable revenue source for Sarepta.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAMONDYS 45\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAMONDYS 45 is a PMO-based therapy for DMD like EXONDYS 51 and VYONDYS 53. It targets a specific exon mutation, offering Sarepta consistent revenue. AMONDYS 45 leverages Sarepta's infrastructure and market access. It contributes to Sarepta's financial stability, with 2024 sales expected to be robust. The drug is a steady performer, even if growth is moderate.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDuchenne Muscular Dystrophy (DMD) Franchise\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSarepta's DMD franchise, including EXONDYS 51, VYONDYS 53, and AMONDYS 45, is a cash cow, consistently generating revenue. The franchise benefits from a strong market presence and reputation. Sarepta has commercialized four approved DMD products: EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS. This established position provides a stable financial base.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eEXONDYS 51, a key product, saw $198.4 million in 2023.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eVYONDYS 53 generated $243.1 million in 2023.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eAMONDYS 45 brought in $224.7 million in 2023.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eELEVIDYS, the newest addition, is expected to grow significantly.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eManufacturing Capabilities\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSarepta's manufacturing prowess solidifies its cash cow status. Their established processes for PMO-based therapies ensure reliable production and supply, meeting market needs. Strategic partnerships boost efficiency and profitability. This operational strength fortifies Sarepta's financial standing.\n\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eIn 2024, Sarepta's revenue reached approximately $1.2 billion, driven by their established therapies.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eSarepta has invested heavily in expanding manufacturing capacity.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eTheir manufacturing efficiency allows for competitive pricing and healthy profit margins.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-CashCows-Icon-Dollar-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSarepta's DMD Therapies: Revenue Surge in 2024!\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSarepta's cash cows include EXONDYS 51, VYONDYS 53, and AMONDYS 45, consistently generating revenue from DMD therapies. These products benefit from established market positions and Sarepta's manufacturing strengths. In 2024, Sarepta's revenue hit around $1.2 billion, with these therapies contributing significantly.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct orange_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eProduct\u003c\/th\u003e\n\u003cth\u003e2023 Revenue (USD millions)\u003c\/th\u003e\n\u003cth\u003e2024 Revenue (Estimated USD millions)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEXONDYS 51\u003c\/td\u003e\n\u003ctd\u003e$198.4\u003c\/td\u003e\n\u003ctd\u003e$350\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eVYONDYS 53\u003c\/td\u003e\n\u003ctd\u003e$243.1\u003c\/td\u003e\n\u003ctd\u003e$400\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAMONDYS 45\u003c\/td\u003e\n\u003ctd\u003e$224.7\u003c\/td\u003e\n\u003ctd\u003e$300\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eD\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eogs\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eEarly-Stage Research Programs (pre-clinical)\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSome of Sarepta's early-stage programs, still pre-clinical, fit the \"Dog\" category. These programs currently operate in low-growth markets. Their market share is also low, with uncertain near-term returns. Sarepta allocated approximately $1.8 billion to R\u0026amp;D in 2023, including these high-risk ventures. These programs need continued investment despite uncertain outcomes.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Investments with Limited Returns\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eStrategic investments with limited returns fit the \"Dogs\" quadrant. These investments fail to generate significant revenue or support core objectives. Sarepta Therapeutics faced a one-time impairment of a strategic investment in 2023. This action reflects the challenges in this area, potentially impacting future returns.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrograms Facing Regulatory Hurdles\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSarepta's \"Dogs\" include programs with regulatory challenges. A clinical hold by the EMA on Elevidys trials creates uncertainty. This could limit market access and affect stock performance. In 2024, Sarepta's stock faced volatility due to these regulatory issues. The EMA's decision directly impacts Elevidys's future.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eTherapies with Limited Patient Populations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eTherapies for small patient populations, or niche markets, can be \"Dogs\" due to limited revenue potential. These address unmet needs, but may not justify continued investment. Sarepta focuses on rare disease therapies. For example, in 2024, Sarepta's revenue was $1.2 billion. These therapies face high development costs.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eLow Revenue Potential\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eUnmet Medical Needs\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eRare Disease Focus\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eHigh Development Costs\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePrograms Outside Core Focus Areas\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eSarepta Therapeutics' programs outside its core focus, like those not related to DMD and LGMDs, might be considered \"Dogs\" in a BCG matrix. These ventures often lack synergy with existing expertise, potentially leading to inefficient resource allocation. Such programs could demand substantial investments in unfamiliar territories, diluting focus. This strategic assessment is crucial for optimizing Sarepta's portfolio and resource deployment. In 2024, Sarepta's R\u0026amp;D expenses were significant, highlighting the need for careful program prioritization.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eLack of Synergy: Programs not aligning with Sarepta's core expertise.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eHigh Investment Needs: Requiring significant financial resources.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eResource Dilution: Potentially diverting from key areas.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eStrategic Reassessment: Critical for portfolio optimization.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Dogs-Icon-Locker-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSarepta's Risky Bets: Early-Stage Programs Under Scrutiny\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSarepta's \"Dogs\" include early-stage, pre-clinical programs with low market share and uncertain returns, representing a significant portion of its R\u0026amp;D spend, which was $1.8B in 2023. These ventures face regulatory hurdles and may address niche markets with limited revenue, as seen with Elevidys's challenges. Programs outside Sarepta's core focus also fall into this category, requiring strategic reassessment.\n\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eCategory\u003c\/th\u003e\n\u003cth\u003eCharacteristics\u003c\/th\u003e\n\u003cth\u003eFinancial Impact (2024)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eEarly-Stage Programs\u003c\/td\u003e\n\u003ctd\u003ePre-clinical, low market share\u003c\/td\u003e\n\u003ctd\u003eHigh R\u0026amp;D costs (approx. $1.8B in 2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory Challenges\u003c\/td\u003e\n\u003ctd\u003eClinical holds, market access limits\u003c\/td\u003e\n\u003ctd\u003eStock volatility\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNiche Markets\u003c\/td\u003e\n\u003ctd\u003eLimited revenue potential\u003c\/td\u003e\n\u003ctd\u003e$1.2B in revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eQ\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003euestion Marks\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSRP-9003 for LGMD2E\/R4\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSRP-9003 is a gene therapy targeting LGMD2E\/R4, classified as a Question Mark in Sarepta's BCG matrix. It's in a high-growth market but has a low market share currently. Sarepta plans to submit a BLA to the FDA in the second half of 2025. Data from the EMERGENE trial are anticipated in the first half of 2025, which will be critical for its future. The global market for gene therapy is projected to reach $11.6 billion by 2028.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSRP-9004 for LGMD type 2D\/R3\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eSRP-9004, a gene therapy for LGMD type 2D\/R3, sits as a Question Mark for Sarepta. It targets a high-growth market but currently holds a low market share. The DISCOVERY study, a phase 1 proof-of-concept, has finished enrollment and dosing. DISCOVERY assesses safety and alpha-sarcoglycan protein expression.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSRP-9005 for LGMD type 2C\/R5\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eSRP-9005, Sarepta's gene therapy for LGMD type 2C\/R5, is a Question Mark. It targets a high-growth market but currently holds a low market share. Sarepta received FDA clearance to proceed with dosing in the COMPASS study. The LGMD market is estimated to reach significant value, presenting growth opportunities for SRP-9005. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003esiRNA Programs for CNS Disorders\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSarepta Therapeutics' siRNA programs for CNS disorders, stemming from the Arrowhead collaboration, are positioned as \"Stars\" in its BCG matrix due to their high growth potential and relatively low current market share. These programs target neurodegenerative diseases and other CNS conditions, marking a new therapeutic area for Sarepta, expanding its focus beyond its core muscle-related treatments. The most advanced candidate, ARO-ATXN2, is undergoing Phase I trials for spinocerebellar ataxia type 2 (SCA2), a debilitating neurodegenerative disease. Sarepta's investment in these programs is driven by the significant unmet medical needs in CNS disorders and the potential for substantial market growth.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eARO-ATXN2, the lead CNS candidate, is in Phase I trials for SCA2.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThese programs represent a strategic expansion into the CNS therapeutic area.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eSarepta aims to capitalize on the high growth potential of the CNS market.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eThe Arrowhead collaboration provides access to siRNA technology.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGene Editing Programs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eSarepta Therapeutics' gene editing programs are categorized as question marks in the BCG matrix. These programs are in their early stages, indicating high potential but also uncertain outcomes. Sarepta is utilizing advanced gene editing technologies to create new therapies for genetic diseases. Due to low market share, these programs face high demands and low returns.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\u003cstrong\u003eEarly-stage development signifies high risk and uncertainty.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eFocus on novel therapies for genetic diseases.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eLow market share contributes to lower returns initially.\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eGene editing programs are resource-intensive.\u003c\/strong\u003e\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/BCG-Content-Questions-Image-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSarepta's Early-Stage Pipeline: High Risk, High Reward\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eQuestion Marks represent Sarepta's early-stage products. They operate in high-growth markets but have low current market share. This category includes gene therapies and gene editing programs, with high risk. Sarepta's R\u0026amp;D expenses were $274.7 million in Q3 2024.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct orange_head blur_tbl\"\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eTherapeutic Area\u003c\/th\u003e\n\u003cth\u003eProduct Type\u003c\/th\u003e\n\u003cth\u003eStatus\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eLGMD\u003c\/td\u003e\n\u003ctd\u003eGene Therapy\u003c\/td\u003e\n\u003ctd\u003ePhase 1-3 trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCNS\u003c\/td\u003e\n\u003ctd\u003esiRNA\u003c\/td\u003e\n\u003ctd\u003ePhase 1 trials\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGenetic Diseases\u003c\/td\u003e\n\u003ctd\u003eGene Editing\u003c\/td\u003e\n\u003ctd\u003eEarly Stage\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003ch2\u003eBCG Matrix \u003cspan style=\"color: #FB9C46;\"\u003eData Sources\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003cp\u003eSarepta's BCG Matrix uses reliable sources such as financial filings, market analyses, and expert evaluations, providing accurate strategic insights. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Data-Sources.svg\" alt=\"Data Sources\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"SAE","offers":[{"title":"Default Title","offer_id":56070265799040,"sku":"sarepta-bcg-matrix","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0899\/6510\/1440\/files\/sarepta-bcg-matrix.png?v=1749415502","url":"https:\/\/swotanalysistemplates.com\/products\/sarepta-bcg-matrix","provider":"SWOT Analysis Templates","version":"1.0","type":"link"}